Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

Abstract Background Marzeptacog alfa (activated) (MarzAA), a novel recombinant activated human factor VII (FVIIa) variant, was developed to provide increased procoagulant activity, subcutaneous (SC) administration, and longer duration of action in people with hemophilia. Objectives To investigate if...

Full description

Bibliographic Details
Main Authors: Johnny Mahlangu, Howard Levy, Marina V. Kosinova, Heghine Khachatryan, Bartosz Korczowski, Levani Makhaldiani, Genadi Iosava, Martin Lee, Frank Del Greco
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
hemophilia
marzeptacog alfa (activated)
prophylaxis
recombinant FVIIa
subcutaneous injection
Online Access:https://doi.org/10.1002/rth2.12576

Internet

https://doi.org/10.1002/rth2.12576

Similar Items